Original ResearchPublished 9 October 2026Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myelomaWojciech Szlasa · Artur Borkowski · Monika Mordak-Domagała · Jacek Kwiatkowski · Katarzyna Malesa · Mateusz Sawicki · Jarosław DybkoFrontiers in Oncologydoi 10.3389/fonc.2026.1915658
ReviewPublished 7 October 2026The 19S proteasome as a therapeutic target in hematologic malignanciesIdaly M. Olivas · Mayra A. Gonzalez-Henry · Saeedeh Darvishi · Evelyn M. Esparza · Anna M. EiringFrontiers in Cell and Developmental Biologydoi 10.3389/fcell.2026.1918833
Original ResearchPublished 12 June 2026Electrophysiological mechanisms behind the differential cardiotoxicity of chemotherapeutic agents Bortezomib and CarfilzomibDario Melgari · Serena Calamaio · Anthony Frosio · Rachele Prevostini · Alessio Malacrida · Luigi Anastasia · Carlo Pappone · Gabriella Nicolini · Guido Cavaletti · Ilaria RivoltaFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1774061
